SAN DIEGO, CA / ACCESSWIRE / May 22, 2015 / Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCQB:INNV)
a company focusing on the commercialization of over-the-counter ("OTC")
and consumer products for men's and women's health, vitality and
respiratory diseases announced today that announced today that it will
present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 in New York City at the Grand Hyatt Hotel.
The Company's presentation by Dr. Bassam Damaj, President & CEO of Innovus Pharma is scheduled to begin at 3:30 p.m. ET.
Dr. Damaj will be discussing the recent progress on:
1. Approval and new products launches in multiple countries
2. US Commercial growth
3. Launch of Androferti(R) in the US
4. Additional new commercial partnerships expected in 2015
5. Update on the approval timeline of Fluticare(TM) by the FDA
The annual Marcum MicroCap
Conference is a showcase for public companies with less than $500
million in market capitalization. For more information or to register,
please visit the conference website at http://www.marcumllp.com/microcap.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma
is an emerging leader in OTC and consumer products for men's and
women's health and vitality. The Company generates revenues from its
lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R) for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide(R), Vesele(R) for promoting sexual and cognitive health, Androferti(R) (in the US and Canada) to support overall male reproductive health and sperm quality and FlutiCare(TM) OTC for Allergic Rhinitis.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com.
Innovus Pharma's Forward-Looking Safe Harbor
Statements
under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release,
the matters described herein contain forward-looking statements that
involve risks and uncertainties that may individually or mutually impact
the matters herein described for a variety of reasons that are outside
the control of the Company, including, but not limited to, receiving
patent protection for any of its products, receiving approval or to be
compliant with the requirements of any relevant regulatory authority
relating to such products, to successfully commercialize such, and to
achieve its other development, commercialization, financial and staffing
objectives. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially
from the forward-looking statements contained herein. Readers are urged
to read the risk factors set forth in the Company's most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and
other filings made with the SEC. Copies of these reports are available
from the SEC's website or without charge from the Company.
Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
SOURCE: Innovus Pharmaceuticals, Inc.